LGALS1 and head and neck cancer: Data from head and neck cancer demonstrated that galectin-1 inhibition enhances anti-PD1 therapy, suggesting that a combination of galectin-1 inhibitors and anti-PD1/PDL1 immune checkpoint synergize for cancer treatment [174].